New Data on BIOTRONIK Orsiro Hybrid Drug-Eluting Stent Demonstrates Enhanced Safety and Three-Times Reduced Risk of Stent Thrombosis

BUELACH, Switzerland, May 26, 2015—BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, announced that positive new data regarding Orsiro, the industry’s first hybrid Drug-Eluting Stent (DES), was presented at EuroPCR 2015 in Paris, France. One year results from the SORT OUT VII trial confirmed Orsiro’s non-inferiority to the bioabsorbable polymer biolimus-eluting Nobori stent in an all-comers population. Encouragingly, patients in the Orsiro arm had a significantly lower rate of definite stent thrombosis, a potentially dangerous adverse event following coronary intervention: only 0.4 percent of Orsiro patients compared with 1.2 percent of patients in the Nobori arm (p=0.03).

During a Hot Line session at EuroPCR, SORT OUT VII principal investigator Dr. Lisette Okkels Jensen, Odense University Hospital, Denmark, described the design and endpoints of the investigatorinitiated randomized, multi-center, two-arm, non-inferiority study. SORT OUT VII compares the ultra-thin strut sirolimus-eluting Orsiro to the biolimus-eluting Nobori DES in the treatment of coronary artery lesions. During the trial, 1,261 patients underwent treatment with Orsiro, while 1,264 patients were treated with Nobori. At one year, the primary endpoint target lesion failure (TLF), defined as a composite of cardiac death, myocardial infarction or target lesion
revascularization within one year, occurred in 3.8 percent of Orsiro patients vs. 4.6 percent of those treated with Nobori DES (p-value for non-inferiority < 0.0001).

During the Hot Line session at EuroPCR, physicians discussed potential explanations for Orsiro’s enhanced safety profile and low rate of stent thrombosis. Orsiro’s unique ultra-thin strut stent design enables greater flexibility than thicker strut designs, and may lead to improved apposition to the vessel wall and quicker endothelialization following percutaneous coronary intervention.

“Several factors, including significantly thinner struts and more controlled drug release, distinguish Orsiro from other bioabsorbable polymer DES,” commented Dr. Jensen. “These refinements could explain the trend towards lower rates of adverse events for Orsiro, exemplified by the considerably reduced risk of definite stent thrombosis seen in SORT OUT VII.” “These highly encouraging results reconfirm those of BIOSCIENCE, the largest independent comparison between Orsiro and Xience Prime to date. BIOSCIENCE confirmed Orsiro’s performance as best-in-class and its results were published in the Lancet,” stated Dr. Daniel Buehler, President, Vascular Intervention at BIOTRONIK. “Now Orsiro has once again proven itself in an even larger, real-world patient population, demonstrating superior efficacy and safety. We are certain that Orsiro’s advanced ultra-thin strut design and outstanding drug deliverability will continue to impress.”